Inhaled Medicines
Optimizing Development through Integration of In Silico, In Vitro and In Vivo Approaches
- 438 pages
- English
- ePUB (mobile friendly)
- Only available on web
Inhaled Medicines
Optimizing Development through Integration of In Silico, In Vitro and In Vivo Approaches
About This Book
Inhaled medicines are widely used to treat pulmonary and systemic diseases. The efficacy and safety of these medicines can be influenced by the deposited fraction, the regional deposition pattern within the lungs and by post-depositional events such as drug dissolution, absorption and clearance from the lungs. Optimizing performance of treatments thus requires that we understand and are able to quantify these product and drug attributes.
Inhaled Medicines: Optimizing Development through Integration of In Silico, In Vitro and In Vivo Approaches explores the current state of the art with respect to inhalation drug delivery, technologies available to assess product performance, and novel in silico methods now available to link in vitro product performance to clinical performance. Recent developments in the latter field, especially the prospect of integration of three-dimensional Computational Fluid Particle Methods (3D-CFPD) with physiologically based pharmacokinetic (PBPK models), unlocks the potential for in silico population studies that can help inform and optimize treatment and product development strategies. In this highly multidisciplinary field, where progress occurs at the intersection of several disciplines of engineering and science, this work aims to integrate current knowledge and understanding and to articulate a clear vision for future developments.
- Considers the healthcare needs driving the field, and where inhaled drugs could have the maximum impact
- Gives a concise account of the state of the art in key areas and technologies such as device and formulation technologies, clinically relevant in vitro performance assessment, medical imaging, as well as in silico modelling and simulation
- Articulates how the combination of in vitro product performance data, medical imaging and simulations technologies in the framework of large scale in silico pre-clinical trials could revolutionize the field
- Provides systematic and thorough referencing to sources offering a more-in-depth analysis of technical issues
Frequently asked questions
Information
Table of contents
- Cover image
- Title page
- Table of Contents
- Copyright
- List of contributors
- Introduction
- Chapter 1. Historical perspective – Disruptive technologies and strategies
- Chapter 2. The API
- Chapter 3. Devices and formulations: General introduction and wet aerosol delivery systems
- Chapter 4. Metered dose inhalers (MDIs)
- Chapter 5. Dry powder inhalers (DPIs)
- Chapter 6. In vitro methods to study dose deposition
- Chapter 7. In silico methods to model dose deposition
- Chapter 8. Non-absorptive clearance from airways
- Chapter 9. Dissolution and drug release
- Chapter 10. Epithelial permeability and drug absorption in the lungs
- Chapter 11. Drug distribution in lung tissue
- Chapter 12. Physiologically-based pharmacokinetic modeling after drug inhalation
- Chapter 13. Inhaled aerosols: Emerging clinical methods
- Chapter 14. Machine learning and in silico methods
- Chapter 15. The emerging state of the art
- Editorial closing remarks
- Index